Myriade

Executive Summary

Myriade has developed Videodrop, a novel nanoparticle analysis platform that rapidly measures size and concentration, enabling real-time monitoring of aggregation and complexation events. The technology addresses critical needs in gene therapy (lentiviral vectors), extracellular vesicle research, and lipid nanoparticle formulation for mRNA therapeutics. By providing a simple, fast, and affordable solution, Videodrop positions itself as a key enabling tool for the growing cell and gene therapy and nanomedicine markets, potentially reducing development times and improving quality control. As a French startup founded in 2020, Myriade is at an early stage but has the potential to capitalize on the increasing demand for nanoparticle characterization tools. The company's focus on AI and machine learning integration could further differentiate its offering. While funding and revenue details are not disclosed, the technology's applicability across multiple high-growth sectors suggests significant upside. If Myriade can secure strategic partnerships or regulatory clearances, it could gain traction in both academic and industrial settings.

Upcoming Catalysts (preview)

• Q3 2026CE Marking for Videodrop60% success
• Q4 2026Strategic Partnership with a Major Gene Therapy Company40% success
• Q2 2026Launch of Videodrop 2.0 with AI-Enhanced Analytics50% success